Artiva Biotherapeutics, Inc. ARTV
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured and stored frozen and ready to ship to a patient's treatment location, making them what we believe to be "off-the-shelf." Our lead product candidate, AlloNK (also known as AB-101), is an allogeneic, non-genetically modified, cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies (mAbs) to drive B-cell depletion. We are currently evaluating AlloNK in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis (RA) and Sjögren's disease (SjD). We are prioritizing refractory RA as our lead indication for AlloNK development. We expect to share initial clinical response data across dose levels from more than 15 refractory RA patients, several of whom will have 6 months or more follow up, in the first half of 2026. In addition, we plan to conduct FDA regulatory interactions in the first half of 2026 to align on the pivotal trial design for AlloNK in refractory RA.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0 | $251.0K | $32.9M | — |
| R&D | $69.5M | $50.3M | $50.3M | — |
| SG&A | $20.3M | $17.2M | $13.9M | — |
| Total operating expenses | $89.8M | $67.5M | $64.2M | — |
| Operating income | -$89.8M | -$67.3M | -$30.7M | — |
| Pre-tax income | -$83.9M | -$65.4M | -$28.6M | — |
| Income tax | $0 | $0 | $72.0K | — |
| Net income | -$83.9M | -$65.4M | -$28.7M | — |
| EPS, basic | -3.43 | -5.81 | -35.78 | — |
| EPS, diluted | -3.43 | -5.81 | -35.78 | — |
| Shares, diluted (wtd. avg.) | 24.4M | 11.3M | 802,747 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $26.7M | $40.2M | $53.8M | $102.8M |
| Short-term investments | $81.3M | $145.2M | $23.5M | — |
| Receivables | — | $0 | $1.0M | — |
| Total current assets | $112.7M | $188.6M | $79.8M | — |
| Property, plant and equipment | $6.6M | $6.4M | $8.1M | — |
| Total assets | $130.9M | $209.6M | $105.1M | — |
| Accounts payable | $355.0K | $1.1M | $614.0K | — |
| Total current liabilities | $13.1M | $12.3M | $12.2M | — |
| Total liabilities | $21.0M | $22.9M | $50.7M | — |
| Retained earnings | -$330.5M | -$246.7M | -$181.3M | — |
| Total equity | $110.0M | $186.6M | -$162.0M | -$140.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$76.8M | -$55.0M | -$47.4M | — |
| Depreciation and amortisation | $2.6M | $2.4M | $2.3M | — |
| Stock-based compensation | $6.8M | $7.0M | $7.1M | — |
| Capital expenditure | $2.6M | $642.0K | $3.3M | — |
| Investing cash flow | $63.4M | -$120.5M | -$26.0M | — |
| Financing cash flow | $9.0K | $162.2M | $24.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197115.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $32.9M | $251.0K | $0 |
| Gross profit | — | — | — | — |
| Net income | — | -$28.7M | -$65.4M | -$83.9M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |